Antonio M. Gutierrez

Health Research Institute Of The Balearic Islands
Palma, PM 07010, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 115 publications

Tumor Mutational Burden as a Prognostic Biomarker in Follicular Lymphoma.

Tumor Mutational Burden as a Prognostic Biomarker in Follicular Lymphoma.

Journal: Cancers
Published: January 26, 2026

Avatrombopag Reduces Platelet Transfusion Requirement in Thrombocytopenia Subsequent to Antineoplastic Therapies in Haematological Patients: The Experience of a Tertiary Centre.

Avatrombopag Reduces Platelet Transfusion Requirement in Thrombocytopenia Subsequent to Antineoplastic Therapies in Haematological Patients: The Experience of a Tertiary Centre.

Journal: Journal of clinical medicine
Published: January 12, 2026

Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma.

Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 05, 2026

Histopathologic Diagnostic Agreement Study in Bone and Soft Tissue Tumors: The SELNET Sarcoma Network Experience.

Histopathologic Diagnostic Agreement Study in Bone and Soft Tissue Tumors: The SELNET Sarcoma Network Experience.

Journal: JCO global oncology
Published: December 15, 2025

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge.

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge.

Journal: Frontiers in pediatrics
Published: December 11, 2025

Real-world resource utilization, toxicity management, and efficacy outcomes of CD20 × CD3 bispecific antibodies in B-cell lymphoma: A study from the GELTAMO network.

Real-world resource utilization, toxicity management, and efficacy outcomes of CD20 × CD3 bispecific antibodies in B-cell lymphoma: A study from the GELTAMO network.

Journal: HemaSphere
Published: December 11, 2025

IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort.

IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort.

Journal: Cancer communications (London, England)
Published: November 13, 2025

Initial report from the SAR-TRACK (SELNET) registry: a multicentric international retrospective analysis on the quality of the management of limb and trunk wall soft-tissue sarcomas (2012-2022) in Ibero-American countries.

Initial report from the SAR-TRACK (SELNET) registry: a multicentric international retrospective analysis on the quality of the management of limb and trunk wall soft-tissue sarcomas (2012-2022) in Ibero-American countries.

Journal: Lancet regional health. Americas
Published: September 30, 2025

Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy.

Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy.

Journal: Leukemia & lymphoma
Published: August 20, 2025

Validation of prognostic scores in patients with HIV-related diffuse large B-cell lymphoma: The value of peripheral blood parameters-A study from the Spanish Lymphoma Group GELTAMO.

Validation of prognostic scores in patients with HIV-related diffuse large B-cell lymphoma: The value of peripheral blood parameters-A study from the Spanish Lymphoma Group GELTAMO.

Journal: British journal of haematology
Published: July 16, 2025

Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study.

Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study.

Journal: Nature communications
Published: June 01, 2025

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.

Journal: Nature cancer
Published: April 16, 2025
Showing 1-12 of 115

Last Updated: 09/26/2026